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Abstract
Background: Vascular endothelial growth factor (VEGF) receptor-2 is the major mediator of the mitogenic, angiogenic, and
vascular hyperpermeability effects of VEGF on breast tumors. Overexpression of VEGF and VEGF receptor-2 is associated
with the degree of pathomorphosis of the tumor tissue and unfavorable prognosis. In this study, we demonstrate that non-
invasive quantification of the degree of tumor vascular permeability to a nanoprobe correlates with the VEGF and its
receptor levels and tumor growth.
Methodology/Principal Findings: We designed an imaging nanoprobe and a methodology to detect the intratumoral
deposition of a 100 nm-scale nanoprobe using mammography allowing measurement of the tumor vascular permeability in
a rat MAT B III breast tumor model. The tumor vascular permeability varied widely among the animals. Notably, the VEGF
and VEGF receptor-2 gene expression of the tumors as measured by qRT-PCR displayed a strong correlation to the imaging-
based measurements of vascular permeability to the 100 nm-scale nanoprobe. This is in good agreement with the fact that
tumors with high angiogenic activity are expected to have more permeable blood vessels resulting in high intratumoral
deposition of a nanoscale agent. In addition, we show that higher intratumoral deposition of the nanoprobe as imaged with
mammography correlated to a faster tumor growth rate. This data suggest that vascular permeability scales to the tumor
growth and that tumor vascular permeability can be a measure of underlying VEGF and VEGF receptor-2 expression in
individual tumors.
Conclusions/Significance: This is the first demonstration, to our knowledge, that quantitative imaging of tumor vascular
permeability to a nanoprobe represents a form of a surrogate, functional biomarker of underlying molecular markers of
angiogenesis.
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Introduction
Angiogenesis is a critical event enabling tumor growth [1–3].
Vascular endothelial growth factor (VEGF) and receptor (VEGFR)
signaling pathway plays a pivotal and rate-limiting role in promoting
tumor-induced angiogenesis [1,2]. Angiogenesis correlates not only
with the onset of tumor development but also with growth,
metastasis and invasion of tumors [4,5]. It is now established that
VEGFR-2 is the major mediator of the mitogenic, angiogenic, and
vascular hyperpermeability effects of VEGF [6–9].
Like most tumors, breast tumors express many angiogenic
factors, such as VEGF and VEGFR, fibroblast growth factor
(FGF)-1, FGF-2, angiopoietin-1 and 2, placenta growth factor,
hypoxia-inducible factor (HIF)-1a, endothelial cell adhesion
molecules (VE-cadherin, PECAM-1), epidermal growth factor,
TGF-a and TGF-b [10–13]. Notably, various clinical studies
demonstrate that higher levels of VEGF overexpression in the
tumor correlate with unfavorable prognosis [14–16]. Indeed, there
is a strong positive correlation between VEGF and VEGFR-2
expression and primary breast cancers and this correlation scales
to the degree of pathomorphosis of the primary tissue [17].
Therefore markers of angiogenesis may describe the degree of
pathomorphosis of breast cancers and quantitative assessment of
these markers may have significant clinical implications. However,
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of the angiogenesis-related factors [1]. However, as angiogenesis
transiently yields immature vessels, they result in ‘leaky’ micro-
vessels. In the recent past, dynamic contrast-enhanced imaging
(DCE-MRI) has been employed to measure tumor vascular
permeability to sub 2 nm scale or 5–10 nm scale contrast agents
[18–20]. Tumor signal enhancement is influenced by the degree of
vascularization, vessel permeability, cellularity and interstitial
pressure [21]. However, while these approaches are promising,
small contrast agents are relatively promiscuous in their leakiness
from vessels and diffuse away quickly requiring the use of
mathematical models to correlate the dynamic changes in signal
enhancement to the physiologic parameters associated with
vascular function [22–25]. In addition, molecular imaging of
angiogenesis biomarkers using positron emission tomography is
beginning to be feasible [26,27].
Here, we investigate a 100 nm nanoprobe, which enables
quantification of tumor vessel permeability in a manner that is
reliable, and not requiring complex analysis of diffusion dynamics.
Due to its size, the 100 nm nanoprobe preferentially accumulates
in solid tumors by passive convective transport through leaky
endothelium, a phenomenon called the enhanced permeation and
retention (EPR) effect [28,29]. In addition, we investigate whether
tumor vascular permeability represents a functional biomarker
that scales to the levels of VEGF and VEGFR-2 overexpression in
tumors. Traditionally biomarkers are cell surface or intracellular
molecular markers – here we suggest that the degree of leakiness of
tumor blood vessels ‘integrates’ underlying tumor microenviron-
mental factors related to angiogenesis, and represents the
underlying tumor pathomorphological status. The nanoprobe
encapsulates a clinically used iodinated contrast agent for x-ray
imaging that enables a quantitative assessment of tumor vessel
leakiness using clinically relevant digital mammography [30,31].
Taking under consideration that mammography is the only
method of low cost mass screening of the general population for
non-palpable breast cancer [32], is widely available and quick and
has a very high spatial resolution, such imaging strategy can be
very practical. Using a breast cancer tumor model where the
tumor EPR of individual rats varies widely [30,31], this study
evaluates whether this variation of tumor EPR to nanoscale
probes, correlates to underlying variation in expression of tumor
angiogenic markers.
Materials and Methods
Ethics Statement
All animals were handled in strict accordance with good animal
practice as defined by the relevant national and/or local animal
welfare bodies, and all animal work was approved by the
Institutional Animal Care and Use Committee (IACUC) of
Georgia Institute of Technology.
Fabrication of the nanoprobe
The nanoprobe was prepared following previously published
methods [31]. A highly concentrated iodine solution (650 mg I/
mL) was prepared by dissolving iodixanol powder (lyophilized
from Visipaque 320; GE Healthcare, Milwaukee, WI) in ultrapure
water under stirring and heating at 70uC. A lipid composition of
DPPC, DSPE-PEG2000 (Genzyme Pharmaceuticals, Cambridge,
MA), and cholesterol (Sigma, St. Louis, MO) in the molar ratio of
55:5:40 was used. The lipids were dissolved in ethanol and
hydrated with the iodine solution at 70uC followed by sequential
extrusion in a Lipex Biomembranes Extruder (Northern Lipids,
Vancouver, Canada) to size the liposomes to ,100 nm. Free,
un-encapsulated iodixanol was replaced by a saline solution
(300 mM NaCl) with the same osmolarity (596 mOsm/kg water)
as the internal iodinated phase of the liposome using a 2-day
dialysis with a 100k MWCO dialysis tubing. Following concen-
tration via diafiltration using MicroKros modules (Spectrum
Laboratories, Rancho Dominguez, CA) with a 50 nm cutoff pore
size, the size of the liposomes was determined by dynamic light
scattering (90 Plus Particle Size Analyzer, Brookhaven Instru-
ments, Holtsville, NY). Prior to administration, the final iodine
levels were quantified through spectrophotometry (at 245 nm).
The liposomal probe contained 75 mg/ml lipids and 165 mg/mL
iodine and 100% of the iodine was encapsulated within the
liposomes. The average diameter of the probe was 102 nm
(standard deviation=11).
Mammary adenocarcinoma cell culture
The 13762 MAT B III cells (American Type Culture
Collection), a rat mammary adenocarcinoma cell line, were
maintained in McCoy’s 5A medium supplemented with 10% fetal
bovine serum and 1% penicillin-streptomycin under conditions of
5% CO2 and 95% humidity at 37uC.
Animal model
For the tumor model, the 13762 MAT B III cell line was used.
Before inoculation, the cells were grown in 90% McCoy’s 5A
medium and 10% fetal bovine serum. A 0.2 mL aliquot containing
10
6 cancer cells was subcutaneously injected into the right flank of
female Fisher rats with ages of 8–9 weeks (Harlan, Indianapolis,
IN). Caliper measurements were used to estimate tumor size and
the tumor volume was calculated as: Vtumor=(d 1
26d2)/2, where
d1 and d2 are the minimum and maximum diameters, respectively.
X-ray imaging
At day 7 after tumor inoculation (tumor volume ,500 mm
3),
the animals were imaged using a clinical digital mammography
system (Senographe 2000D, GE Healthcare, Milwaukee, WI). To
maximize the number of photons with energies above the K-edge
of iodine (approx. 33.2 keV) [33], the imaging studies were
performed with a 49 kVp, 63 mAs x-ray spectrum, using a
rhodium target and a 25 mm thick rhodium filter with an added
0.254 mm thick copper filter.
After the initial imaging session at day 7 after tumor inoculation
(t=0), a group of animals (group A, n=6) was imaged at defined
time points (t=24, and 72 h) after intravenous (IV) injection of the
probe at a dose of 455 mg/kg body weight (b.w.) iodine.
Immediately after the last imaging session, the animals were
euthanized, tumors were excised, and total RNA was extracted for
quantitative real-time reverse transcriptase-polymerase chain
reaction (qRT-PCR). Care was taken to obtain the entire tumor
without any surrounding tissue.
To evaluate whether the degree of EPR scales to the tumor
growth rate, a different group of animals (group B, n=11) was
imaged before (t=0) and at defined time points (t=24, 48 and
120 h) after IV injection of the probe at a dose of 455 mg/kg b.w.
iodine at day 7 after tumor inoculation. The tumor growth of each
animal was monitored at 24 h intervals using caliper measure-
ments. Tumor growth was allowed to progress until the animal
showed signs of morbidity, at which point, the animals were
euthanized using a CO2 chamber.
Quantitative RT-PCR
qRT-PCR was used to quantify mRNA expression profiles of
genes that are closely associated with angiogenesis. Immediately
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euthanized and tumors were excised. Total RNA was extracted
from the entire tumor and muscle (control) of each animal (n=6)
by using RNeasy Maxi RNA extraction kit (Qiagen, Chatsworth,
CA) and the protocols therein. Purified RNA was quantified using
the Quant-IT Ribogreen reagent (Invitrogen Life Technologies,
Carlsbad, CA). Total RNA (2 mg) was converted into cDNAby using
Thermoscript RT-PCR system (Invitrogen Life Technologies,
Carlsbad, CA). Primers targeting VEGF-A (NM_031836.1) For-
ward– CGTCTACCAGCGCAGCTATTG and Reverse- CACA-
CAGGACGGCTTGAAGAT; KDR (VEGFR-2) (NM_013062.1)
Forward- TTGGCAAATACAACCCTTCAGAT and Reverse-
CACTCAGTCACCAACACCCTTTC; and endogenous control
hypoxanthine phosphoribosyltransferase-1 (HPRT1) (NM_012583.2)
Forward – TGTTTGTGTCATCAGCGAAAGTG and Reverse -
CTGCTAGTTCTTTACTGGCCACATC were designed using
Primer Express 3.0 software (Applied Biosystems, Foster city, CA),
t oy i e l da na m p l i c o no f,100 base-pair length. PCR amplification
efficiencies were assessed for each primer-set using cDNA equivalents
of 1, 2, 5, 10, 20, 50 and 100 ng of total RNA. qRT-PCR was
conducted on an ABI Step-One-Plus real-time PCR system (Applied
Biosystems, Foster City, CA) in 20 ml reactions. Each reaction
consisted of a cDNA equivalent of 20 ng of total RNA, 10 mlP o w e r H
SYBR Green PCR Master Mix (Applied Biosystems, Foster City,
CA) and forward and reverse primers at 0.9 mM concentration. Each
sample was assayed in triplicate for both target and endogenous
control, and relative quantitative gene expression was assessed using
the DDCT method. The levels of target gene expression were
calculated following normalization of endogenous control for each
sample, and presented as relative units. The relative gene expression
of each tumor was computed by normalizing its value to the tumor
with the highest value (a value of 1 corresponds to the tumor with the
highest gene expression).
Histological analysis
For a qualitative histological validation of the imaging and
qRT-PCR studies, a separate group of animals (group C, n=2)
was injected at day 7 with the probe at a dose of 455 mg/kg b.w.
iodine tagged with rhodamine. At 48-h post-injection, the animals
were perfused transcardially with phosphate buffered saline (PBS)
followed by 4% paraformaldehyde in PBS. The tumors were
explanted and post-fixed overnight in 4% paraformaldehyde in
PBS. The fixed tumors were soaked in 30% sucrose (w/v) in PBS
at 4uC for cryosectioning. Serial sections of 16 mm thickness were
collected using a cryostat (Leica CM 300, Leica, Bannockburn,
IL). The tissue slices were immunohistochemically stained for
VEGFR-2 using a mouse monoclonal antibody (Santa Cruz
Biotechnology, Santa Cruz, CA). The tissues were also stained
with the nuclear stain DAPI. The staining procedures followed
established methods [34]. The tumor sections were imaged at 46
on the Nikon Eclipse 80i upright microscope using a Microfire
CCD camera (Optronics, Golate, CA) that interfaced with the
Neurolucida software (MicroBrightField Bioscience, Williston,
VT) to obtain a montage of each section. The histological analysis
was performed to verify the presence of extravascular intratumoral
accumulation of the probe and its location with respect to the
tumor vasculature and VEGFR-2 expression.
Image analysis
The sequential image acquisitions at different time points
provided the dynamics of the nanoprobe’s accumulation in the
tumor over time. The images were analyzed using ImageJ software
(NIH, Bethesda, MD) following previously described methods
[30,31].
Data and statistical analysis
To determine the significance of the relative gene expression
levels of the tumors, one-way ANOVA with post-hoc Bonferroni
test was performed (SPSS 15, Chicago, IL). A p-value less than
0.05 was used to confirm significant differences at the 95%
confidence level. The Anderson-Darling test was performed to
verify that the data followed a normal distribution. The tumor
signal enhancement profiles and tumor growth curves were fitted
into an exponential function [35] using nonlinear regression
(Levenberg-Marquardt algorithm) to compute the enhancement
rate constant (K
enhancement) and the tumor growth rate constant
(K
tumor growth), respectively. The K
enhancement and K
tumor growth
constants represent a measure of each animal’s tumor vascular
permeability to the probe and its tumor growth, respectively. The
correlation between the signal enhancement and the tumor growth
rate or relative gene expression was determined using Pearson’s
correlation. A p-value less than 0.05 was used to confirm
significant differences at the 95% confidence level. The correctness
of the model was determined by examining the residuals plots and
other statistical tests.
Results
Tumor imaging
To eliminate signal from the blood vessels and transparently
image the EPR of the probe, contrast-enhanced imaging was
performed with IV injection of the probe at a dose of 455 mg/kg
b.w. iodine which resulted in a concentration below the threshold
for detection of iodine in the blood [31]. This allowed detection of
the intratumoral extravascular deposition of the probe with no
interference from vascular signal. Fig. 1 shows the pre-injection
(t=0) and post-injection images (t=24 and 72 h). In the post-
injection images, no blood vessels were visible in the normal tissue
while the spleen and the tumor were enhanced. Spleen
enhancement is consistent with clearance of the liposomal probe
via the Reticulo Endothelial System (RES) [36].
Correlation of angiogenesis biomarkers to EPR imaging
When tumors were monitored for 3 days post-injection, it was
observed that the x-ray absorption in tumors due to extravas-
cular nanoprobe varied widely both spatially and temporally
suggesting that each tumor had different tumor vessel leakiness.
Fig. 2.a summarizes the 3-day time course of the tumor
enhancement of a group of animals injected with the nanoprobe
(group A). Following imaging, the animals were euthanized,
tumors were excised, and total RNA was extracted for qRT-
PCR. A significant difference in the gene levels can be observed
from one animal to the next (Fig. 2.b). Some tumors displayed 3–
5 times less VEGF and VEGFR-2 than others. Importantly, the
relative gene expression level of each tumor strongly correlated
to its tumor enhancement as imaged by mammography (Fig. 2.c
and d).
Histological evaluation of intratumoral distribution of the
probe
In a previous study [31], we showed the MAT B III tumor is
characterized by a highly vascularized peripheral rim and an
internal core with low vascularization. Notably, the extravasated
nanoprobes were localized in the well-vascularized periphery of
the tumor in a patchy distribution. In the current study,
immunofluorescence microscopy was performed to qualitatively
determine the microdistribution of VEGFR-2 and nanoprobe
deposition. As shown in Fig. 3.a, VEGFR-2 (shown in green) is
predominantly found in the periphery whereas lower levels are
Vascular Permeability and VEGF
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red) localized in the periphery of the tumor showing a patchy
distribution similar to our previous observations [31]. Fig. 3.b
and c show two locations from the same histological slide
representing two regions with different degree of angiogenesis as
indicated by the different levels of VEGFR-2. Of note, more
nanoprobes deposited in the region of high levels (Fig. 3.b) than
low levels of VEGFR-2 (Fig. 3.c). The deposition of the
nanoprobes usually coincided with the regions of high levels of
VEGFR-2 which indicates leakier blood vessels. Thus, these data
corroborate the imaging data and are consistent with enhanced
accumulation of nanoprobes in regions of high angiogenic
activity.
Correlation of tumor growth to imaging of EPR
To evaluate whether the degree of EPR scales to the tumor
growth rate, a different group of animals (group B) was imaged
before and after IV injection of the probe and the tumor growth of
each animal was measured for several days after imaging.
Similarly to before, the tumor enhancement profiles exhibited
dissimilar patterns in different animals (Fig. 4.a). Fig. 4.b shows the
tumor growth rate of each individual animal displaying a wide
variability. Importantly, a significant correlation between the
imaging measurements and the tumor growth was observed.
Higher intratumoral deposition of the nanocarrier as imaged with
mammography indicating leakier vasculature correlated to a faster
tumor growth rate. To quantitatively understand the relation of
the imaging measurement and tumor growth, we calculated the
tumor growth rate constant (K
tumor growth) and signal enhancement
rate constant (K
enhancement) of each animal. Fig. 4.c demonstrates a
strong correlation between K
tumor growth and K
enhancement with the
more leaky tumors (high K
enhancement) having faster tumor progress
(high K
tumor growth) and vice versa.
Discussion
Clinical studies have shown the VEGF expression varies
among tumors [14–16]. In this study, we also observed a high
variability in the expression of tumor VEGF-A and VEGFR-2
among the different animals (as measured by qRT-PCR) with
the standard deviation being 37 and 52% of the mean value,
respectively. This is consistent with a previous study that
reported similar variability of angiogenesis biomarkers in animal
tumor models [37]. The imaging data verified our hypothesis
that the higher expression of angiogenic biomarkers in specific
tumors resulted in more permeable blood vessels which
Figure 1. Radiographic images of a rat breast tumor model obtained using a clinical digital mammography system. The images
display the 3-day intratumoral fate of the probe (a) before, (b) 24 and (c) 72 h after administration of the probe at a dose of 455 mg/kg b.w. iodine. In
the post-injection images no blood vessels were visible in the normal tissue while spleen and tumor were clearly seen. Yellow and brown dotted
circles indicate the location of the tumor and spleen, respectively. In the insets, a magnification (56) of the tumor at each time point is shown.
doi:10.1371/journal.pone.0005843.g001
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the nanoprobe. Not surprisingly, we observed that the tumor
EPR (as measured by mammography) varied widely from one
animal to the next which is consistent with previous studies
demonstrating a wide variation in the intratumoral accumulation
of nanoscale liposomal agents within tumors of the same ‘stage’
and size in preclinical [38–42] and clinical studies [43,44].
Actually, it is well established that the degree of tumor
vasculature leakiness differs not only among same type tumors
but even spatially within the same tumor [45–47].
Furthermore, the tumors with the leakier blood vessels were the
ones with the faster growth rates. Even though the tumor model
was developed in a controlled manner by inoculating the same
type and number of cells into the same location of rats with the
same age and weight, a wide range of tumor growth rates was
observed (the standard deviation was about 30% of the mean
value). The variable tumor growth rate observed in our study is
consistent with human breast tumor xenografts in nude mice
where the tumor growth curve had standard deviations of about
15–25% of the mean value [39]. Our results display one more
example that tumors represent a very heterogeneous population of
different cells with a complex microenvironment that is strongly
affected by angiogenesis. Notably, many clinical studies have
shown that increased VEGF overexpression in breast tumors
correlate with more unfavorable prognosis [14–17]. In another
clinical study [48], analysis of core biopsies from 155 breast cancer
patients showed that tumor angiogenesis correlated with tumor
histological analysis suggesting that assessment of tumor angio-
genesis can be used as a selection criterion for patients to undergo
a more aggressive therapeutic protocol.
The feasibility of our imaging method to evaluate tumor
angiogenesis was demonstrated on a single tumor model although
human cancer as a disease is much more heterogeneous than one
experimental tumor model in terms of both tumors and hosts [49].
The MAT BIII tumor and its vasculature grow rapidly while
human tumors exhibit a range of growth rates. To address this
variability in tumor growth rates and its relationship to their EPR
and angiogenesis status, further testing in more tumor models is
required to capture the proliferative range of human tumors.
The significance of tumor vascular permeability and its
association to angiogenesis, tumor growth, metastatic tendency,
and delivery of macromolecular and nanoscale therapeutics has
been well documented and debated [50]. We have recently shown
that tumor vascular permeability governs the access of therapeutic
agents to tumors [30,31]. The current study indicates that vessel
leakiness is strongly associated with the environment of tumors, the
tumor growth and the rate of angiogenesis. Such non-invasive,
imaging method can potentially provide an a priori determination
of the degree of tumor aggressiveness and facilitate personalized
therapy. In addition, the realization of the effects of tumor
angiogenesis on tumor growth and metastasis [3] has led to the
development of anti-angiogenic therapeutic strategies for the
Figure 2. Comparison of the imaging-based EPR measurements to gene expression of VEGF and VEGFR-2. (a) The 3-day pattern of the
enhancement upon injection of the probe to a group of rats (n=6) indicated a high variability in the tumors leakiness. (b) Relative gene expression of
VEGF and VEGFR-2 as measured using qRT-PCR also exhibited a high variability (* indicates p,0.005; data presented as mean6standard deviation).
(c–d) The relative gene expression level of each tumor was strongly correlated to its tumor enhancement as imaged by mammography (VEGF-A:
R
2=0.873, p,0.005; VEGFR-2: R
2=0.824, p,0.002). Each animal is assigned the same color in all the graphs (e.g. purple indicates animal number 4).
doi:10.1371/journal.pone.0005843.g002
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localized in the periphery of the tumor showing a patchy distribution (DAPI was used as a nuclear stain; shown in blue; 46magnification). In the
same slide, the highly vascularized peripheral rim is shown to have high levels of VEGFR-2 (shown in green) compared to the less vascularized inner
core. (b) High intratumoral deposition of the nanoprobe is found in a region with high levels of VEGFR-2. (c) Relatively few nanoprobes accumulated
in a region of low VEGFR-2 levels.
doi:10.1371/journal.pone.0005843.g003
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Besides tumor staging and size, the clinician typically has little
information to design, track and customize the anti-angiogenic
therapy for each tumor in a patient-specific manner [20,51]. To
date, there exist no clinical tools to determine the tumor VEGF
expression profile enabling identification of the patients who can
possibly benefit from such therapies. In addition, the ability to
assess VEGF target inhibition independently of tumor response is
Figure 4. Comparison of the imaging-based measurement of tumor EPR to tumor growth rate. (a) The 4-day pattern of the enhancement
following injection of the probe (455 mg/kg iodine) to a group of rats (n=11) indicated a high variability in the tumors leakiness. (b) The tumor of
each animal displayed a different growth rate as indicated by the variable tumor growth curves. (c) The correlation of the tumor growth (K
tumor growth)
and the imaging measurement (K
enhancement) was statistically significant (R
2=0.785; p,0.001).
doi:10.1371/journal.pone.0005843.g004
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changes in tumor growth to become apparent. One recent
example demonstrating the critical role that tumor vasculature
plays in determining outcomes of antiangiogenic therapies comes
from the work of Jain [52,53], where it is demonstrated that the
restructuring of tumor vasculature (a process termed ‘normaliza-
tion’) leads to better chemotherapeutic outcomes. While anti-
angiogenic agents focus on destroying tumor related blood vessels
compromising the efficiency of subsequent chemotherapy, optimal
scheduling and dosing of these therapies can ‘normalize’ the
abnormal tumor vasculature for better delivery of oxygen
(eliminating hypoxia and its complications) and drugs. Measure-
ment of vessel leakiness using our nanoprobe and mammography
can potentially provide prognostic assessment and monitoring of
anti-angiogenic therapies of breast cancer. We hypothesize such
strategy would also be possible with tomographic methods (e.g.
CT) extending the application to other types of cancer.
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